Search

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2019

What Happens When DR Treatment Is Less Aggressive?

Roger A. Goldberg, MD, MBA

Show Description +

Roger Goldberg, MD, MBA, details results from a post hoc analysis of the RISE/RIDE extension study. Dr. Goldberg asks what happened when patients no longer maintained aggressive treatment for DR, and finds data illustrating the relationship between injection frequency and disease severity.

Posted: 7/11/2019

Up Next

Hyperreflective Foci and Pathologic Risk

Hyperreflective Foci and Pathologic Risk

Bozho Todorich, MD, PhD

Novel Combination Technique for Closing Challenging Macular Holes

Novel Combination Technique for Closing Challenging Macular Holes

Robert Sisk

A Novel Retinal Tamponade

A Novel Retinal Tamponade

Tommy Stryjewski, Tony Stefater

1-Year Primary Outcome Data From RECOVERY

1-Year Primary Outcome Data From RECOVERY

Charles Wykoff, MD, PhD

Ranibizumab PDS: How LADDER Informed ARCHWAY

Ranibizumab PDS: How LADDER Informed ARCHWAY

Arshad Khanani, MD

Intravitreal Injections and Clinical Resources

Intravitreal Injections and Clinical Resources

Christina Weng, MD

CST Fluctuations in HAWK and HARRIER

CST Fluctuations in HAWK and HARRIER

Chirag Jhaveri, MD

STAIRWAY: Faricimab for Wet AMD

STAIRWAY: Faricimab for Wet AMD

Philip Ferrone

HARBOR Post-Hoc Analysis: Vision Outcomes and the Presence of Fluid

HARBOR Post-Hoc Analysis: Vision Outcomes and the Presence of Fluid

Nancy Holekamp, MD

Preview to ASRS with Dr. Packo

Preview to ASRS with Dr. Packo

Kirk Packo, MD

Preview to ASRS 2019 With Dr. Pollack

Preview to ASRS 2019 With Dr. Pollack

John Pollack, MD

Higher-Level Analysis of OCT Features

Higher-Level Analysis of OCT Features

Justis Ehlers, MD

The Winning Pitch: The Shark Tank of Retina

The Winning Pitch: The Shark Tank of Retina

David Williams

Rethinking Risk in Fovea-Sparing RRDs

Rethinking Risk in Fovea-Sparing RRDs

James Major Jr., MD

Back to All Videos

What Happens When DR Treatment Is Less Aggressive?

Roger A. Goldberg, MD, MBA

Roger Goldberg, MD, MBA, details results from a post hoc analysis of the RISE/RIDE extension study. Dr. Goldberg asks what happened when patients no longer maintained aggressive treatment for DR, and finds data illustrating the relationship between injection frequency and disease severity.

Posted: 7/11/2019

Please log in to leave a comment.

More From ASRS: 2019 Coverage

Higher-Level Analysis of OCT Features

Higher-Level Analysis of OCT Features

Justis Ehlers, MD

The Winning Pitch: The Shark Tank of Retina

The Winning Pitch: The Shark Tank of Retina

David Williams

Rethinking Risk in Fovea-Sparing RRDs

Rethinking Risk in Fovea-Sparing RRDs

James Major Jr., MD

Hyperreflective Foci and Pathologic Risk

Hyperreflective Foci and Pathologic Risk

Bozho Todorich, MD, PhD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2019.